Form 8-K - Current report:
SEC Accession No. 0001193125-23-202313
Filing Date
2023-08-03
Accepted
2023-08-03 08:10:58
Documents
15
Period of Report
2023-07-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d472276d8k.htm   iXBRL 8-K 30699
2 EX-10.1 d472276dex101.htm EX-10.1 34991
3 EX-99.1 d472276dex991.htm EX-99.1 212938
7 GRAPHIC g472276g0803051118039.jpg GRAPHIC 3274
  Complete submission text file 0001193125-23-202313.txt   445038

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA alny-20230731.xsd EX-101.SCH 2849
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE alny-20230731_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alny-20230731_pre.xml EX-101.PRE 11260
9 EXTRACTED XBRL INSTANCE DOCUMENT d472276d8k_htm.xml XML 3376
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 231138194
SIC: 2834 Pharmaceutical Preparations